|Bid||0.0000 x 3000|
|Ask||0.0000 x 800|
|Day's range||3.1500 - 3.4000|
|52-week range||3.1400 - 8.4700|
|Beta (5Y monthly)||0.14|
|PE ratio (TTM)||N/A|
|Earnings date||18 Nov 2021 - 22 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||18.00|
ARIDIS PHARMACT (ARDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.
Aridis Pharmaceuticals, Inc. ( NASDAQ:ARDS ) is possibly approaching a major achievement in its business, so we would...